BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, announced that Loramyc has obtained Marketing Authorization in Switzerland for the treatment of oropharyngeal candidiasis in immunocompromised patients (mainly cancer and AIDS patients with oral opportunistic infections).
"This approval represents an important milestone for Loramyc which is now registered in 12 countries in Europe, including Switzerland. This step will thus reinforce Loramyc opportunity for a European commercial agreement for which we are actively seeking a suitable partner involved in the supportive care field, said Dominique Costantini, president and CEO of BioAlliance Pharma. "Loramyc value has also recently been strengthened by the US FDA acceptance of its New Drug Application," added Dominique Costantini.
As a preferred partner for hospital-based specialists, BioAlliance Pharma is a company which develops and markets innovative products in France, especially in the fields of opportunistic infections and chemotherapy complications.